Zefei Jiang
A5076149259- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Research Studies
- Bone health and treatments
- Brain Metastases and Treatment
- Global Cancer Incidence and Screening
- COVID-19 and healthcare impacts
- Breast Lesions and Carcinomas
- Cancer-related Molecular Pathways
- PARP inhibition in cancer therapy
- Histone Deacetylase Inhibitors Research
Chinese PLA General Hospital
2008-2025
Chinese People's Liberation Army
2010-2025
Air Force General Hospital PLA
2024-2025
Peking University Shenzhen Hospital
2025
Guangdong Pharmaceutical University
2025
Hebei North University
2025
307th Hospital of Chinese People’s Liberation Army
2015-2024
People's Liberation Army No. 150 Hospital
2024
The University of Sydney
2024
University of Shanghai for Science and Technology
2024
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
Neratinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor. The efficacy and safety of neratinib were evaluated in two cohorts patients with advanced ErbB2-positive breast cancer-those those without prior trastuzumab treatment-in open-label, multicenter, phase II trial.Patients the (prior trastuzumab, n = 66; no 70) received oral 240 mg once daily. primary end point was 16-week progression-free survival (PFS) rate for evaluable population 63; 64), as assessed by...
Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free (DRFS) hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of prespecified primary outcome analysis an additional analysis.This global, phase III,...
Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy of pyrotinib versus lapatinib, both combination with capecitabine, women human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer open-label, multicenter, randomized II study.Chinese patients HER2-positive relapsed or previously treated taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400...
Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase II aims to evaluate optimum level for efficacy and safety apatinib monotherapy in heavily pretreated patients metastatic triple negative breast cancer (mTNBC) China. IIa was first performed among 25 previously treated anthracycline and/or taxane. All received p.o. a 4-week cycle. Subsequently, IIb 59 activated,...
Abstract Molecular profiling of circulating extracellular vesicles (EVs) provides a promising noninvasive means to diagnose, monitor, and predict the course metastatic breast cancer (MBC). However, analysis EV protein markers has been confounded by presence soluble counterparts in peripheral blood. Here we use rapid, sensitive, low-cost thermophoretic aptasensor (TAS) profile cancer-associated profiles plasma EVs without interference proteins. We show that signature (a weighted sum eight...
<h3>Importance</h3> Prospective assessment of treatments known to benefit patients in global clinical trials specific racial groups is essential. <h3>Objective</h3> To compare the efficacy, safety, and tolerability adding pertuzumab trastuzumab docetaxel vs placebo, trastuzumab, Asian with ERBB2-positive early or locally advanced breast cancer. <h3>Design, Setting, Participants</h3> This multicenter, double-blind, placebo-controlled phase 3 trial enrolled 329 women (T2-3, N0-1, M0) cancer N2...
The usefulness of 3D deep learning-based classification breast cancer and malignancy localization from MRI has been reported. This work can potentially be very useful in the clinical domain aid radiologists diagnosis.To evaluate efficacy convolutional neural network (CNN) for diagnosing localizing lesions at dynamic contrast enhanced (DCE) data a weakly supervised manner.Retrospective study.A total 1537 female study cases (mean age 47.5 years ±11.8) were collected March 2013 to December...
Lapatinib is an oral small-molecule tyrosine kinase inhibitor of both epidermal growth factor receptor and human 2 (HER2). This study designed to test whether the addition lapatinib paclitaxel improves overall survival (OS) compared with placebo plus in patients HER2-overexpressing metastatic breast cancer (MBC).This phase III, randomized, double-blind assessed efficacy safety newly diagnosed HER2-positive MBC. The primary end point was OS. Secondary points included progression-free (PFS),...
Previous trials showed that antiangiogenesis or anti-programmed death protein 1/programmed ligand 1 (PD-1/PD-L1) monotherapy only marginal effect in triple-negative breast cancer (TNBC). Preclinical studies demonstrated antiangiogenic therapy could sensitize to PD-1/PD-L1 blockade via reprogramming tumor microenvironment. Combinational treatment of checkpoint and for TNBC has not been reported.Patients with advanced less than three lines systemic were enrolled an open-label, non-comparative,...
The tumor suppressor gene, PTEN, has previously been demonstrated to be involved in breast tumorigenesis and progression. aim of the present study was investigate expression significance PTEN carcinomas, detect mutation frequency sporadic carcinoma tissues determine association between promoter methylation gene expression. Immunohistochemical methods were used analyze 146 cases 10 normal tissue closely adjacent carcinoma. Polymerase chain reaction-single strand conformation polymorphism...
Abstract Background: PI3K pathway activation is a hallmark of hormone receptor-positive (HR+) BC cells resistant to endocrine therapy (ET). Preclinical and early clinical data suggest that combining the pan-PI3K inhibitor BUP (BKM120) with ET may provide benefits in this setting. BELLE-2 (NCT01610284) first randomized Phase III trial assess efficacy safety combined FULV HR+ advanced BC, including prospective analysis whether status measured archival tumor tissue ctDNA predictive benefit....
Background: Pyrotinib is an irreversible pan-ErbB inhibitor targeting epidermal growth factor receptor, human receptor 2 (HER2), and HER4. This randomized, double-blinded phase 3 study evaluated the efficacy safety of pyrotinib plus capecitabine for HER2-positive local relapsed or metastatic breast cancer. Methods: Patients who had been treated with trastuzumab taxanes were randomized (2:1) to receive either oral placebo (400 mg, qd) (1,000 mg/m2, bid on days 1–14) 21-day cycles, using...
Developing guidelines for the diagnosis and treatment of common cancers in China based on evidence-based practice, availability products, up-to-date advances precision medicine is one basic tasks Chinese Society Clinical Oncology (CSCO).In recent years, medical resources has become a major concern clinical guidelines, which particularly important developing countries or socioeconomically diverse territories.China world's largest country, with large territory uneven economic academic...
Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine has survival benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer. We further assessed addition of pyrotinib to trastuzumab docetaxel the neoadjuvant setting. In this multicenter, double-blind, phase 3 study (PHEDRA), treatment-naive women early or locally advanced cancer were randomly assigned (1:1) receive four cycles oral placebo (400 mg) once daily, intravenous (8 mg/kg loading dose,...
Abstract Platinum is recommended in combination with gemcitabine the treatment of metastatic triple-negative breast cancer (mTNBC). We conduct a randomized phase 3, controlled, open-label trial to compare nab-paclitaxel/cisplatin (AP) gemcitabine/cisplatin (GP) mTNBC patients (ClinicalTrials.gov NCT02546934). 254 untreated randomly receive AP (nab-paclitaxel 125 mg/m² on day 1, 8 and cisplatin 75 1) or GP (gemcitabine 1250 intravenously every 3 weeks until progression disease, intolerable...
Abstract The randomized, multicenter, double-blind, placebo-controlled, phase III PEONY trial (NCT02586025) demonstrated significantly improved total pathologic complete response (primary endpoint) with dual HER2 blockade in HER2-positive early/locally advanced breast cancer, as previously reported. Here, we present the final, long-term efficacy (secondary endpoints: event-free survival, disease-free overall survival) and safety analysis (62.9 months’ median follow-up). Patients (female; n =...